New therapeutic options for advanced forms of thyroid cancer

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Introduction: While the vast majority of patients with thyroid cancer have an excellent prognosis, those with more aggressive courses experience significant morbidity and mortality. Advanced forms of thyroid cancer are typically refractory to standard therapy. Numerous agents with potential usefulness in the treatment of advanced thyroid cancer have recently come under study. Areas covered: This article reviews agents identified through a systematic review of the scientific literature as being under investigation for treatment of advanced thyroid cancer. A search of both PubMed and the NCI Clinical Trials website was performed to identify such agents having reached Phase II or III testing. Improved understanding of cancer cell signaling pathways has led to the identification of > 500 kinases as potential therapeutic targets. Additional agents of interest include those that inhibit neoangiogenesis, alter epigenetic factors or stimulate antitumor immune reactions. While presently available agents have shown promise in improving progression-free survival (PFS), complete responses are not seen and significant adverse side effects are encountered. Expert opinion: The development of numerous new anticancer agents holds the promise of treatment regimens that will extend PFS and ultimately overall survival in patients with advanced thyroid cancer. Anticipated future developments include individualized, multimodal treatment regimens based on specific tumor cell biology and driver mutations.

Original languageEnglish (US)
Pages (from-to)225-241
Number of pages17
JournalExpert Opinion on Emerging Drugs
Volume19
Issue number2
DOIs
StatePublished - 2014

Fingerprint

Thyroid Neoplasms
Disease-Free Survival
Therapeutics
Combined Modality Therapy
Expert Testimony
PubMed
Epigenomics
Antineoplastic Agents
Cell Biology
Neoplasms
Phosphotransferases
Clinical Trials
Morbidity
Mutation
Survival
Mortality

Keywords

  • Anaplastic thyroid cancer
  • Anti-CEA antibodies
  • B-raf inhibitors
  • Differentiated thyroid cancer
  • Histone deacetylase inhibitors
  • Kinase inhibitors
  • Medullary thyroid cancer
  • Thyroid cancer
  • Thyroid cancer therapy

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Medicine(all)

Cite this

New therapeutic options for advanced forms of thyroid cancer. / Bernet, Victor; Smallridge, Robert Christian.

In: Expert Opinion on Emerging Drugs, Vol. 19, No. 2, 2014, p. 225-241.

Research output: Contribution to journalArticle

@article{f51c8eea55f746f8a0647b1834cfbf75,
title = "New therapeutic options for advanced forms of thyroid cancer",
abstract = "Introduction: While the vast majority of patients with thyroid cancer have an excellent prognosis, those with more aggressive courses experience significant morbidity and mortality. Advanced forms of thyroid cancer are typically refractory to standard therapy. Numerous agents with potential usefulness in the treatment of advanced thyroid cancer have recently come under study. Areas covered: This article reviews agents identified through a systematic review of the scientific literature as being under investigation for treatment of advanced thyroid cancer. A search of both PubMed and the NCI Clinical Trials website was performed to identify such agents having reached Phase II or III testing. Improved understanding of cancer cell signaling pathways has led to the identification of > 500 kinases as potential therapeutic targets. Additional agents of interest include those that inhibit neoangiogenesis, alter epigenetic factors or stimulate antitumor immune reactions. While presently available agents have shown promise in improving progression-free survival (PFS), complete responses are not seen and significant adverse side effects are encountered. Expert opinion: The development of numerous new anticancer agents holds the promise of treatment regimens that will extend PFS and ultimately overall survival in patients with advanced thyroid cancer. Anticipated future developments include individualized, multimodal treatment regimens based on specific tumor cell biology and driver mutations.",
keywords = "Anaplastic thyroid cancer, Anti-CEA antibodies, B-raf inhibitors, Differentiated thyroid cancer, Histone deacetylase inhibitors, Kinase inhibitors, Medullary thyroid cancer, Thyroid cancer, Thyroid cancer therapy",
author = "Victor Bernet and Smallridge, {Robert Christian}",
year = "2014",
doi = "10.1517/14728214.2014.894017",
language = "English (US)",
volume = "19",
pages = "225--241",
journal = "Expert Opinion on Emerging Drugs",
issn = "1472-8214",
publisher = "Informa Healthcare",
number = "2",

}

TY - JOUR

T1 - New therapeutic options for advanced forms of thyroid cancer

AU - Bernet, Victor

AU - Smallridge, Robert Christian

PY - 2014

Y1 - 2014

N2 - Introduction: While the vast majority of patients with thyroid cancer have an excellent prognosis, those with more aggressive courses experience significant morbidity and mortality. Advanced forms of thyroid cancer are typically refractory to standard therapy. Numerous agents with potential usefulness in the treatment of advanced thyroid cancer have recently come under study. Areas covered: This article reviews agents identified through a systematic review of the scientific literature as being under investigation for treatment of advanced thyroid cancer. A search of both PubMed and the NCI Clinical Trials website was performed to identify such agents having reached Phase II or III testing. Improved understanding of cancer cell signaling pathways has led to the identification of > 500 kinases as potential therapeutic targets. Additional agents of interest include those that inhibit neoangiogenesis, alter epigenetic factors or stimulate antitumor immune reactions. While presently available agents have shown promise in improving progression-free survival (PFS), complete responses are not seen and significant adverse side effects are encountered. Expert opinion: The development of numerous new anticancer agents holds the promise of treatment regimens that will extend PFS and ultimately overall survival in patients with advanced thyroid cancer. Anticipated future developments include individualized, multimodal treatment regimens based on specific tumor cell biology and driver mutations.

AB - Introduction: While the vast majority of patients with thyroid cancer have an excellent prognosis, those with more aggressive courses experience significant morbidity and mortality. Advanced forms of thyroid cancer are typically refractory to standard therapy. Numerous agents with potential usefulness in the treatment of advanced thyroid cancer have recently come under study. Areas covered: This article reviews agents identified through a systematic review of the scientific literature as being under investigation for treatment of advanced thyroid cancer. A search of both PubMed and the NCI Clinical Trials website was performed to identify such agents having reached Phase II or III testing. Improved understanding of cancer cell signaling pathways has led to the identification of > 500 kinases as potential therapeutic targets. Additional agents of interest include those that inhibit neoangiogenesis, alter epigenetic factors or stimulate antitumor immune reactions. While presently available agents have shown promise in improving progression-free survival (PFS), complete responses are not seen and significant adverse side effects are encountered. Expert opinion: The development of numerous new anticancer agents holds the promise of treatment regimens that will extend PFS and ultimately overall survival in patients with advanced thyroid cancer. Anticipated future developments include individualized, multimodal treatment regimens based on specific tumor cell biology and driver mutations.

KW - Anaplastic thyroid cancer

KW - Anti-CEA antibodies

KW - B-raf inhibitors

KW - Differentiated thyroid cancer

KW - Histone deacetylase inhibitors

KW - Kinase inhibitors

KW - Medullary thyroid cancer

KW - Thyroid cancer

KW - Thyroid cancer therapy

UR - http://www.scopus.com/inward/record.url?scp=84901258971&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84901258971&partnerID=8YFLogxK

U2 - 10.1517/14728214.2014.894017

DO - 10.1517/14728214.2014.894017

M3 - Article

VL - 19

SP - 225

EP - 241

JO - Expert Opinion on Emerging Drugs

JF - Expert Opinion on Emerging Drugs

SN - 1472-8214

IS - 2

ER -